title: Cabazitaxel for castration-resistant prostate cancer.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Shigeta
authors.forename: Yuji
authors.initials: Y
authors.lastname: Miura
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Naito
authors.forename: Toshimi
authors.initials: T
authors.lastname: Takano
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology; D013318:Stroke Volume / Q000187:drug effects; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D043823:Taxoids; C552428:cabazitaxel; D008942:Mitoxantrone; D011241:Prednisone